arrow
C

Chitra Hosing

the university of texas
H指数:72
被引数:2.1万
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ex Vivo Mesenchymal Progenitor Cell-based Cord Blood Cell Expansion and Exofucosylation to Enhance Transplant Engraftment

离体间充质祖细胞介导的脐带血细胞扩增及外岩藻糖基化,以增强移植植入效果

2025-11-190
PRE
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

作者更正: 同种异体NK细胞与双特异性先天细胞衔接器治疗难治性复发性淋巴瘤: 1期试验

2025-06-260
PRE
Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality

造血干细胞移植后的限制性通气缺陷与死亡率增加有关

2025-02-010
PRE
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial

自体非清髓性造血干细胞移植治疗弥漫性皮肤系统性硬化症:前瞻性、单臂试验中识别毒性及长期结局的疾病危险因素

2025-01-140
OAAI
Corrigendum to ‘Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation’ [Transplantation and Cellular Therapy 29/3 (2023) 204-204]

更正:‘造血细胞移植后肺功能受损初始检测后的闭塞性细支气管炎综合征风险因素’ [移植与细胞治疗 29/3 (2023) 204-204]

2024-11-170
PRE
Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis

年龄对AL淀粉样变性自体干细胞移植结局的影响

BLOOD
IF23.1
2024-11-050
PRE
Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

供者年龄和供-受者性别不匹配对HLA匹配的亲属与非亲属供者造血细胞移植结局的影响

BLOOD
IF23.1
2024-11-050
PRE
Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

供者年龄较轻的半相合造血干细胞移植疗效改善

BLOOD
IF23.1
2024-11-050
PRE
Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

在Mycosis Fungoides和Sezary Syndrome中的大细胞转化:445例分析

BLOOD
IF23.1
2024-11-050
PRE
Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT)

异基因干细胞移植后高危蕈样肉芽肿大细胞转化(MF-LCT)患者的结局

BLOOD
IF23.1
2024-11-050
PRE
Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis

心脏AL淀粉样变性移植结局的预测因素

BLOOD
IF23.1
2024-11-050
PRE
Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

大剂量分次马利兰、氟达拉滨、克拉屈滨、替莫唑胺和维奈克拉(Cladillac)预处理方案用于极高危AML/MDS:一项Ⅱ期临床试验

BLOOD
IF23.1
2024-11-050
PRE
Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study

免疫效应细胞治疗后针对白喉、破伤风和肺炎球菌的体液免疫和抗体反应: 一项前瞻性研究

2024-09-190
OAAI
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
2024-09-012
PRE
Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation
2024-02-291
OAAI
Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study
2024-02-050
PRE
Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma

体外扩增脐血自然杀伤细胞联合利妥昔单抗及大剂量化疗和自体干细胞移植治疗b细胞非霍奇金淋巴瘤

2024-02-014
OAAI
Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation
2024-02-013
PRE